Precision Neuroscience Secures $102 Million in Series C Funding to Advance Breakthrough Neurological Treatments

Precision Neuroscience is thrilled to announce that we have successfully raised $102 million in our latest funding round, a pivotal boost that will accelerate our mission to deliver groundbreaking treatments for the estimated one billion patients globally suffering from neurological illnesses. This substantial investment underscores the confidence our investors have in our innovative approach to neurology and the potential of our uniquely designed brain-computer interface (BCI). Unlike traditional methods, our BCI is focused on being minimally invasive, easily removable, and highly efficient in processing vast amounts of data, making it a safer and more effective option for managing various neurological disorders. Our technology not only promises to enhance the quality of life for patients but also lies at the intersection of human and artificial intelligence, paving the way for unprecedented advancements in patient-driven neurological care. As we move forward, these funds will allow us to significantly scale our research and development efforts, expand our clinical trials, and ultimately bring our pioneering solutions to those in need. We are excited about the possibilities that lie ahead and remain deeply committed to our vision of transforming neurology. To discover more about Precision Neuroscience and our revolutionary work in connecting human intelligence with AI, please visit our website at www.precisionneuro.io. Thank you to our investors for believing in our mission, and to everyone who supports our journey towards improving neurological health for countless individuals.